Evaluation of the characteristics of leucyl-tRNA synthetase (LeuRS) inhibitor AN3365 in combination with different antibiotic classes

• Published in: European journal of clinical microbiology & infectious diseases 2016-11, Vol.35 (11), p.1857-1864
• Main Authors: Monteferrante, C. G., Jirgensons, A., Varik, V., Hauryliuk, V., Goessens, W. H. F., Hays, J. P.
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Biomedical and Life Sciences; Biomedicine; Drug Interactions; Drug Resistance, Bacterial; Enzyme Inhibitors - pharmacology; Gram-Negative Bacteria - drug effects; Gram-Negative Bacteria - enzymology; Gram-Positive Bacteria - drug effects; Gram-Positive Bacteria - enzymology; Internal Medicine; Leucine-tRNA Ligase - antagonists & inhibitors; Medical Microbiology; Mutation; Original; Original Article
• ISSN: 0934-9723; 1435-4373; 1435-4373
• DOI: 10.1007/s10096-016-2738-1

Aminoacyl tRNA synthetases are enzymes involved in the key process of coupling an amino acid to its cognate tRNA. AN3365 is a novel antibiotic that specifically targets leucyl-tRNA synthetase, whose development was halted after evaluation in phase II clinical trials owing to the rapid selection of resistance. In an attempt to bring AN3365 back into the developmental pipeline we have evaluated the efficacy of AN3365 in combination with different classes of antibiotic and characterized its mechanism of action. Although we detect no synergy or antagonism in combination with a range of antibiotic classes, a combination of AN3365 with colistin reduces the accumulation of AN3365-resistant and colistin resistance mutations. We also demonstrate that treatment with AN3365 results in the dramatic accumulation of the alarmone (p)ppGpp, the effector of the stringent response—a key player in antibiotic tolerance.